NCT04440514 Endoscopic Preperitoneal Parastomal Hernia Repair (ePauli Repair)
| NCT ID | NCT04440514 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sykehuset Innlandet HF |
| Condition | Parastomal Hernia |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2020-06-01 |
| Primary Completion | 2035-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2020-06-01 with a primary completion date of 2035-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Observational study on laparoscopic and robotic extraperitoneal mesh repair of parastomal hernia, employing TAR.
Eligibility Criteria
Inclusion Criteria: * parastomal hernia with need of repair Exclusion Criteria: * \< 18 years
Contact & Investigator
jan r lambrecht, PhD
PRINCIPAL INVESTIGATOR
Sykehuset Innlandet Hospital Trust
Frequently Asked Questions
Who can join the NCT04440514 clinical trial?
This trial is open to participants of all sexes, studying Parastomal Hernia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04440514 currently recruiting?
Yes, NCT04440514 is actively recruiting participants. Contact the research team at jan@lambrecht.no for enrollment information.
Where is the NCT04440514 trial being conducted?
This trial is being conducted at Brumunddal, Norway, Hamar, Norway.
Who is sponsoring the NCT04440514 clinical trial?
NCT04440514 is sponsored by Sykehuset Innlandet HF. The principal investigator is jan r lambrecht, PhD at Sykehuset Innlandet Hospital Trust. The trial plans to enroll 150 participants.